$3.06
0.97% yesterday
Nasdaq, Apr 07, 10:00 pm CET
ISIN
US92915B1061
Symbol
VYGR
Sector
Industry

Voyager Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Voyager Therapeutics, Inc. Classifications & Recommendation:

Buy
100%

Voyager Therapeutics, Inc. Price Target

Target Price $16.10
Price $3.06
Potential
Number of Estimates 10
10 Analysts have issued a price target Voyager Therapeutics, Inc. 2026 . The average Voyager Therapeutics, Inc. target price is $16.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 12 Analysts recommend Voyager Therapeutics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Voyager Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Voyager Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 80.00 66.14
68.00% 17.32%
EBITDA Margin -98.20% -160.69%
294.14% 63.64%
Net Margin -77.31% -138.50%
218.90% 79.16%

12 Analysts have issued a sales forecast Voyager Therapeutics, Inc. 2025 . The average Voyager Therapeutics, Inc. sales estimate is

$66.1m
Unlock
. This is
17.32% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$147m 83.36%
Unlock
, the lowest is
$4.0m 95.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $80.0m 68.00%
2025
$66.1m 17.32%
Unlock
2026
$65.5m 0.92%
Unlock
2027
$69.7m 6.36%
Unlock
2028
$87.5m 25.56%
Unlock
2029
$66.4m 24.09%
Unlock

4 Analysts have issued an Voyager Therapeutics, Inc. EBITDA forecast 2025. The average Voyager Therapeutics, Inc. EBITDA estimate is

$-106m
Unlock
. This is
35.29% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-59.5m 24.26%
Unlock
, the lowest is
$-155m 97.30%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-78.6m 162.12%
2025
$-106m 35.29%
Unlock
2026
$-107m 0.58%
Unlock
2027
$-118m 10.68%
Unlock
2028
$-136m 15.32%
Unlock
2029
$-129m 5.53%
Unlock

EBITDA Margin

2024 -98.20% 294.14%
2025
-160.69% 63.64%
Unlock
2026
-163.12% 1.51%
Unlock
2027
-169.74% 4.06%
Unlock
2028
-155.91% 8.15%
Unlock
2029
-194.01% 24.44%
Unlock

12 Voyager Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Voyager Therapeutics, Inc. net profit estimate is

$-91.6m
Unlock
. This is
48.11% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-33.4m 46.01%
Unlock
, the lowest is
$-142m 130.09%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-61.8m 138.05%
2025
$-91.6m 48.11%
Unlock
2026
$-89.8m 2.00%
Unlock
2027
$-87.9m 2.05%
Unlock
2028
$-55.0m 37.50%
Unlock
2029
$-79.4m 44.40%
Unlock

Net Margin

2024 -77.31% 218.90%
2025
-138.50% 79.16%
Unlock
2026
-136.98% 1.10%
Unlock
2027
-126.15% 7.91%
Unlock
2028
-62.80% 50.22%
Unlock
2029
-119.44% 90.19%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.13 -1.67
138.05% 47.79%
P/E negative
EV/Sales negative

12 Analysts have issued a Voyager Therapeutics, Inc. forecast for earnings per share. The average Voyager Therapeutics, Inc. EPS is

$-1.67
Unlock
. This is
47.79% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.61 46.02%
Unlock
, the lowest is
$-2.60 130.09%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.13 138.05%
2025
$-1.67 47.79%
Unlock
2026
$-1.64 1.80%
Unlock
2027
$-1.61 1.83%
Unlock
2028
$-1.00 37.89%
Unlock
2029
$-1.45 45.00%
Unlock

P/E ratio

Current -2.72 190.07%
2025
-1.83 32.72%
Unlock
2026
-1.87 2.19%
Unlock
2027
-1.90 1.60%
Unlock
2028
-3.05 60.53%
Unlock
2029
-2.11 30.82%
Unlock

Based on analysts' sales estimates for 2025, the Voyager Therapeutics, Inc. stock is valued at an EV/Sales of

-0.82
Unlock
and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.68 157.63%
2025
-0.82 20.10%
Unlock
2026
-0.82 0.93%
Unlock
2027
-0.78 5.98%
Unlock
2028
-0.62 20.36%
Unlock
2029
-0.81 31.74%
Unlock

P/S ratio

Current 2.11 4.20%
2025
2.55 20.95%
Unlock
2026
2.58 0.92%
Unlock
2027
2.42 5.98%
Unlock
2028
1.93 20.35%
Unlock
2029
2.54 31.73%
Unlock

Current Voyager Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Canaccord Genuity
Locked
Locked
Locked Mar 13 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 13 2025
Cantor Fitzgerald
Locked
Locked
Locked Mar 12 2025
Wedbush
Locked
Locked
Locked Mar 12 2025
Wells Fargo
Locked
Locked
Locked Mar 12 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 03 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 27 2025
Analyst Rating Date
Locked
Canaccord Genuity:
Locked
Locked
Mar 13 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 13 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 12 2025
Locked
Wedbush:
Locked
Locked
Mar 12 2025
Locked
Wells Fargo:
Locked
Locked
Mar 12 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 03 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today